Anti-Glial/Neuronal Nuclear Antibody-Type 1 (AGNA-1) Titer, Spinal Fluid
Use
The test for anti-glial/neuronal nuclear antibody-type 1 (AGNA-1) is useful for reporting end titer results from cerebrospinal fluid (CSF) specimens. It is particularly significant for serological evaluation in patients presenting with subacute neurological disorders of undetermined etiology, especially those with a risk factor of primary lung carcinoma. This test assists in directing a focused search for cancer, investigating neurological symptoms associated with or following cancer therapy, and differentiating autoimmune neuropathies from neurotoxic effects of chemotherapy. It also plays a role in monitoring the immune response during cancer therapy and detecting early recurrence of cancer in previously seropositive patients.
Special Instructions
Test is only orderable as a reflex. If the immunofluorescence pattern suggests AGNA-1, then this test is performed with an additional charge. Serum is preferred over spinal fluid unless interfering antibodies are present.
Limitations
AGNA-1 can be difficult to detect by immunofluorescence when it coexists with other neuronal nuclear autoantibodies, unless AGNA-1's titer is higher than the coexisting antibodies. It is not detectable by Western blot. This test was developed by Mayo Clinic according to CLIA requirements but has not been cleared or approved by the FDA.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay (IFA))
Biomarkers
LOINC Codes
- 93455-5
- 94355-5
Result Turnaround Time
6-8 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
2 mL
Minimum Volume
1 mL
Container
Sterile vial
Causes for Rejection
Gross hemolysis, Gross lipemia, Gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |